The Significant Influence of the Neuroendocrine Component on the Survival of Patients with Gastric Carcinoma Characterized by Coexisting Exocrine and Neuroendocrine Components

Table 4

Univariate and multivariate analyses for patients with a NE component.

Variables		Univariate analysis		Multivariate analysis
		HR (95% CI)	p value	HR (95% CI)	p value
Gender	M	1 (reference)
	F	0.828 (0.248, 2.770)	0.760
Age	≤60	1 (reference)
	>60	2.310 (0.964, 5.536)	0.061
Location	Upper	1 (reference)		1 (reference)
	Middle	0.278 (0.065, 1.190)	0.084	0.338 (0.074, 1.551)	0.163
	Lower	0.210 (0.049, 0.897)	0.035	0.391 (0.083, 1.848)	0.236
Curvature	Lesser	1 (reference)
	Greater	1.703 (0.349, 8.321)	0.511
Diameter	≤4.64	1 (reference)		1 (reference)
	>4.64	3.076 (1.356, 6.976)	0.007	2.585 (1.112, 6.006)	0.027
Lauren type	Intestinal	1 (reference)
	Diffuse	0.941 (0.289, 3.068)	0.920
	Mixed	1.092 (0.406, 2.938)	0.861
pT stage	1	1 (reference)
	2	0.619 (0.039, 9.922)	0.734
	3	1.775 (0.233, 13.527)	0.580
	4	3.297 (0.405, 26.867)	0.265
pN stage	0	1 (reference)		1 (reference)
	1	0.934 (0.223, 3.915)	0.926	0.952 (0.226, 4.021)	0.947
	2	0.827 (0.196, 3.486)	0.796	0.862 (0.200, 3.721)	0.842
	3	3.359 (1.198, 9.417)	0.021	2.953 (1.051, 8.293)	0.040
pTNM stage	I	1 (reference)
	II	2.023 (0.240, 17.041)	0.517
	III	4.081 (0.541, 30.764)	0.172
NE component 0<NE≤70		1 (reference)
NE component 70<NE<100/		1.718 (0.756, 3.903)	0.196
Ki-67 ()	≤56.21	1 (reference)
	>56.21	2.696 (0.834, 8.710)	0.097
Mitotic index	≤37.71	1 (reference)
	>37.71	1.887 (0.696, 5.118)	0.212
Adjuvant therapy	N	1 (reference)
	Y	1.245 (0.449, 3.452)	0.674